Functions of Macrophages in the Maintenance of Intestinal Homeostasis

Shuai Wang,1,2 Qianhong Ye,2 Xiangfang Zeng,2 and Shiyan Qiao2

1Department of Animal Nutrition and Feed Science, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China
2State Key Laboratory of Animal Nutrition, Beijing Key Laboratory of Biofeed Additives, Ministry of Agriculture Feed Industry Centre, China Agricultural University, Beijing 100193, China

Correspondence should be addressed to Shiyan Qiao; qiaoshiyan@cau.edu.cn

Received 21 October 2018; Revised 3 December 2018; Accepted 16 December 2018; Published 18 March 2019

Copyright © 2019 Shuai Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Intestinal macrophages constitute the largest pool of macrophages in the body and have emerged as crucial sentinels for pathogen recognition and elimination. The source and development of intestinal macrophages, as well as their distinct properties have been well documented. Intestinal macrophages exert their functions in the maintenance of intestinal homeostasis by shaping host-microbiota symbiosis, managing gut inflammation, crosstalking with T cells, and facilitating wound repair. Recently, nutritional regulation of intestinal macrophages has attracted substantial attention and is becoming a promising approach to disease prevention and control. Understanding the mechanisms employed by intestinal macrophages in mediating intestinal immune homeostasis and inflammation, as well as the mode of action of dietary nutrients in the modulating functions of intestinal macrophages, represents an opportunity to prevent and control inflammatory bowel diseases.

1. Introduction

The gastrointestinal tract mucosa is continually exposed to a high load of antigens, ranging from dietary proteins and commensal microbiota to clinically important pathogens, viruses, and toxins. A single layer of intestinal epithelial cells form a barrier between the lamina propria and the luminal contents of the intestine. Intestinal macrophages that reside in the subepithelial lamina propria (LP) represent the most abundant mononuclear phagocytes in the body and have emerged as crucial sentinels for the maintenance of intestinal homeostasis [1]. As the first phagocytic cells of the innate immune system, intestinal macrophages engulf and clear pathogens, cellular debris, and bacterial products, constantly maintaining a balance between immunity against foreign pathogens and tolerance to commensals [2]. Nonetheless, the cellular and molecular mechanisms by which this critical balance is achieved remain relatively unknown. Due to the crucial role of macrophages in the initiation and development of intestinal immunity, therapeutically manipulating macrophages are becoming an attracting way for disease prevention and treatment. In this review, we focus our attention on intestinal macrophages, describing the recent insights into the role of intestinal macrophages in maintaining gut homeostasis and managing gut inflammation. Finally, we will discuss the nutritional modulation of intestinal macrophage function and the potential of nutritional strategies aimed at manipulating intestinal macrophages to ameliorate inflammatory bowel disorders.

2. Intestinal Macrophages

Intestinal macrophages, which constitute the largest pool of macrophages in the body, are the most abundant mononuclear phagocytes in the LP. Macrophages in the intestine are identified by the expression of F4/80 and CD64 markers, as well as the integrin CD11b [3, 4]. Mature intestinal macrophages also express high levels of the chemokine receptor CX3CR1 [5]. However, with the deepening research on the intestinal mucosal immune system, these characteristic markers have not been able to distinguish intestinal macrophages from other cells. For instance, dendritic cells share
many phenotypic characteristics with macrophages, such as MHCII and CD11b [6, 7]. Thus, additional markers need to be discovered to distinguish intestinal macrophages from other cells.

3. Source and Development of Intestinal Macrophages

Intestinal macrophages, which are thought to play a pivotal role in orchestrating intestinal mucosal immune responses, have received relatively little research attention compared with other tissue macrophages. Macrophages are present in virtually the entire body. In contrast to macrophages from many other tissues, those in the LP of the intestine are continuously replenished from recruited Ly6C⁺ blood monocytes under steady state or in response to inflammation [8]. These peripheral-blood monocytes develop from hematopoietic stem cells in the bone marrow. During monocyte development, hematopoietic stem cells divide and differentiate into monoblasts, then promonocytes, and finally monocytes in the presence of macrophage colony-stimulating factor [9]. The CCL2-CCR2 axis plays a critical role in the migration of Ly6C⁺ monocytes from the bone marrow to the peripheral blood [10, 11]. Bone-marrow monocytes have been classified into two principal subsets with distinct migratory properties in mice [12]. In steady state condition, Ly6C⁺ monocytes enter the gut mucosa and differentiate into mature CX3CR1⁺F4/80⁺ macrophages via a CX3CR1⁺ transitional stage. These CX3CR1⁺ macrophages produce PGE2 and help maintain integrity of the gut epithelial layer [13]. Additionally, CX3CR1⁺ macrophages also secrete interleukin-10 (IL-10), an anti-inflammatory cytokine that maintains mucosal homeostasis [14, 15]. Likewise, lamina propria macrophages drive differentiation of regulatory T (Treg) cells in the intestinal mucosa through production of IL-10 [16]. Signaling mediated by the IL-10 receptor plays a pivotal role in the hyporesponsiveness of murine or human intestinal macrophages. Macrophage-derived IL-10 also maintains survival and expansion of inducible FoxP3⁺ Treg cells in the LP, which are crucial for tolerance of orally ingested antigens in mice [17]. Impaired production of IL-10 would result in macrophage hyperactivity and inflammatory bowel disease in mice and humans [18, 19]. The IL-10–IL-10R axis, especially IL-10 receptor, is indispensable for gut homeostasis. Macrophages unable to sense IL-10, due to loss of IL-10 receptor, play a central role in the development of severe spontaneous colitis [20]. When intestinal homeostasis is disturbed by infection or inflammation, the normal pattern of monocyte differentiation is disrupted. Ly6C⁺ monocytes and their CX3CR1⁺ derivatives are recruited to the intestinal mucosa in large numbers during incidents of acute colitis [6]. The CX3CR1⁺ macrophages produce large amounts of TNF-α, IL-6, IL-12, and IL-23, as well as iNOS, rendering them responsive to TLR stimulation to become proinflammatory effector cells [5, 21, 22]. In addition, Ly6C⁺ monocytes may recruit other innate effector cells via production of chemokines. For example, Waddell et al. (2011) found that Ly6C⁺ monocytes orchestrated the recruitment of eosinophils through secretion of CCL11 (eotaxin) in a mouse model of dextran sodium sulfate- (DSS-) induced colitis. Importantly, these elicited Ly6C⁺ monocytes are able to directly control the pathogenic effects of neutrophils and, in particular, the production of TNF-α and ROS by neutrophils in a PGE2-dependent manner [13].

4. The Distinct Properties of Intestinal Macrophages

The epithelial surface of the gastrointestinal tract is exposed to a great mass of bacteria as well as a large number and diversity of dietary antigens. The primary role of intestinal macrophages is to act as innate effector cells in the intestinal LP. To cope with this large antigenic load that may potentially cross the intestinal LP, macrophages in the intestine form some functional adaptations to preserve local tissue homeostasis [23]. Unlike their progenitor cells and blood monocytes, human intestinal macrophages show greatly diminished expression of costimulatory molecules, such as CD40, CD80, and CD 86 [24]. In addition, human resident intestinal macrophages exhibit greater phagocytic activity without initiating an inflammatory response due to their low, or even absent, expression of innate response receptors, including receptors for LPS (CD14), Fca (CD89), Fcy (CD64, CD32, and CD16), CR3 (CD11b/CD18), and CR4 (CD11c/CD18) [25]. This hyporesponsiveness enables intestinal macrophages to act as efficient scavengers without inducing inflammation that would normally occur and impair intestinal homeostasis when macrophages encounter pathogens. Finally, human intestinal macrophages also lack the triggering receptor expressed on myeloid cells-1 (TREM-1) [26]. TREM-1 is a cell surface molecule expressed on peripheral blood neutrophils and monocytes/macrophages. This cell surface molecule is an efficient amplifier of inflammation because TREM-1-mediated activation causes enhanced expression of proinflammatory mediators (e.g., TNF, IL-1β, and IL-6) or an upregulation of several cell surface molecules indicating oxidative burst (e.g., CD40, CD86, and CD 32) [27]. The absence of TREM-1 expression on human intestinal macrophages probably contributes to the low level of inflammation observed under physiological conditions, which can be regarded as a further adaptation of intestinal macrophages to the specific environment of the intestinal LP.

5. Functions of Intestinal Macrophages

5.1. Shaping Host-Microbiota Symbiosis. Given the trillions of microorganisms that live in the intestine, the intestinal immune system must continually sustain a balance between immunity to pathogens and tolerance of commensals to prevent needless immune responses against inoffensive bacteria. A question arises about how the immune system discriminates between pathogenic and commensal bacteria. One explanation is that the immune system can discriminate between commensals and pathogens through recognition of symbiotic microbial molecules. Bacteroides fragilis is a prominent gut commensal. The symbiosis factor, polysaccharide A (PSA) of B. fragilis, is essential for B. fragilis to suppress T-helper 17 (Th17) responses during homeostatic colonization.
In addition, resident macrophages are hyporesponsive to Toll-like receptor (TLR) stimulation but constantly produce pro-IL-1β, whereas pathogens but not commensals could elicit mature IL-1β through the NLRC4 inflammasome. Inflammasomes are molecular platforms inducing the activation of caspase-1, which lead to the secretion of mature and biologically active IL-1β [29] (Figure 1). Additionally, intestinal macrophages can also help maintain intestinal homeostasis by inducing production of anti-inflammatory cytokines, as well as engulfing and degrading commensals [25].

5.2. Managing Gut Inflammation. An increasing body of evidence suggests that macrophages located in the intestinal mucosa have an important role in maintaining the tolerance of commensals while staying responsive to pathogens [2]. However, disorders in enteric bacterial recognition by intestinal macrophages can result in chronic intestinal inflammation, such as inflammatory bowel diseases (IBDs) [30]. Proinflammatory macrophages (CX3CR1<sup>hi</sup> cells) isolated from an inflamed intestine produce large amounts of IL-1β, IL-6, TNF-α, IL-23, and NO [13, 31–33]. Besides contributing to tissue damage, these factors mediate the bacterial function of macrophages. TNF-α has many functions such as activation and chemotaxis of neutrophils to kill microbes [34]. NO, synthesized by iNOS, is a short-lived gas that possesses beneficial roles in antibacterial activity of macrophages against pathogens [35]. Heme-oxygenase-1 (HMOX-1) is an antioxidant and anti-inflammatory enzyme produced by CX3CR1<sup>hi</sup> macrophages. Previous studies reported that HMOX-1 also helps to control inflammation in the intestine via enhancing phagocytic activity of macrophages [36]. It is well recognized that IL-23 is essential for host defense during the early phase of infection. For example, during the early phase of *Citrobacter rodentium* infection, invasion of the pathogen leads to secretion of IL-23 [37]. IL-23 can stimulate IL-22 production under several infectious conditions [38], and IL-22 seems to be indispensable in protecting the integrity of the intestinal epithelial layer. IL-22 also plays a key role in preventing the spread of pathogens by inducing antimicrobial peptides and chemokines that recruit immune cells to the site of infection [39]. Therefore, proinflammatory intestinal macrophages are essential for protection against pathogenic bacterial infections such as salmonellosis and colibacillosis [25, 40].

5.3. Crosstalk with T Cells. Macrophages can also maintain immunological homeostasis via induction or expansion of regulatory T cells in the intestine [41, 42]. FoxP3<sup>+</sup> T<sub>reg</sub> cells play a critical role in intestinal homeostasis. Mice deprived of T<sub>reg</sub> cells are more susceptible to colitis [43]. In the LP, CD11<sup>hi</sup>F4/80<sup>−</sup>CD11<sup>+</sup> macrophages induce differentiation of FoxP3<sup>+</sup> T<sub>reg</sub> cells via a mechanism dependent on retinoic acid, IL-10, and transforming growth factor-β.
(TGF-β) [16]. In parallel, the number of FoxP3⁺ Treg cells in the intestine is correlated with macrophage numbers [44]. Moreover, these FoxP3⁺ Treg cells have also been reported to have the ability to inhibit inflammatory activity of Th1 and Th17 cells in inflamed intestines [45]. Collectively, these studies emphasize the function of macrophages as a bridge between innate and adaptive immunity against infections in the intestine.

5.4. Wound Repair. Epithelial damage concerned with the impairment of the intestinal mucosal layer occurs following mechanical injury and is a characteristic of inflammatory bowel disease. Repair of the mucosal layer is crucial for alleviating gut inflammation and regaining intestinal homeostasis. Macrophages contribute to the coordination of tissue repair [46] (Figure 2). Macrophages are a major source of IL-10 for healing intestinal mucosa. IL-10 activates the cAMP response element-binding protein (CREB) signaling. This signaling enhances secretion of WNT-1-inducible signaling protein 1 (WISP-1) that in turn promotes WNT signaling, epithelial cell proliferation, and wound healing in the intestine. Additionally, intestinal macrophages also secrete prostaglandin E2 (PGE2) and hepatocyte growth factor (HGF), which stimulate renewal and differentiation of the intestinal epithelium.

**Figure 2**: Macrophages contribute to the coordination of wound healing. Macrophages recruited to the sites of intestinal injury produce IL-10, resulting in the activation of cAMP response element-binding protein (CREB) signaling. This signaling enhances secretion of WNT-1-inducible signaling protein 1 (WISP-1) that in turn promotes WNT signaling, epithelial cell proliferation, and wound healing in the intestine. Additionally, intestinal macrophages also secrete prostaglandin E2 (PGE2) and hepatocyte growth factor (HGF), which stimulate renewal and differentiation of the intestinal epithelium.

6. Influence of Nutrition on Intestinal Macrophage Function

An important role for enteral nutrients in modulation of intestinal macrophages is emerging. Many diet-derived luminal metabolites that are processed by gut microbiota, such as short-chain fatty acids (SCFAs), vitamins, and bile acids, have been demonstrated to regulate immune cell functions in the intestine. In addition, certain nutrients derived from the diet, without processing by microbiota, also possess immunomodulatory functions [51, 52]. Not surprisingly, the effects of dietary nutrients on the regulation of intestinal macrophages have attracted substantial attention in recent years.

6.1. Fatty Acids. Short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate are metabolites of gut bacterial fermentation of dietary fiber that are not digested by host in the small intestine [53]. Increasing evidence suggests that SCFAs have a potential to modulate the immune response in the intestine. Administration of SCFA can alleviate intestinal inflammation and lesions in patients with colitis or in murine colitis models [54, 55]. These immunomodulatory effects of SCFA are probably due to
their anti-inflammatory properties [56–58]. Recent work has demonstrated that butyrate can modulate intestinal macrophage function, thereby contributing to homeostasis in the intestines [2] (Figure 3). Treatment of macrophages with butyrate results in downregulation of LPS-induced proinflammatory mediators, such as IL-6, IL-12, and nitric oxide. These effects are attributed to inhibition of histone deacetylases by butyrate [2].

6.2. Functional Amino Acids. A deficiency of dietary amino acids is known to cause malnutrition and then impair the intestinal immune system, increasing susceptibility of the host to infectious disease. Accumulating evidence indicates that dietary amino acids have the capability of regulating intestinal macrophage functions [52, 59]. For instance, deprivation of enteral nutrients related to total parenteral nutrition results in a decrease in the number of IL-10-producing macrophages in the small intestine of mice. Whereas dietary amino acids are able to directly regulate replenishment of intestinal macrophages and their IL-10 secretion [52]. However, further studies are needed to elucidate the mechanism by which dietary amino acids modulate macrophage function. It was found that dietary histidine prevented the development of colitis in an IL-10-deficient murine model. Whereas dietary amino acids are able to directly regulate replenishment of intestinal macrophages and their IL-10 secretion [52]. However, further studies are needed to elucidate the mechanism by which dietary amino acids modulate macrophage function. It was found that dietary histidine prevented the development of colitis in an IL-10-deficient murine model. The protective effects of histidine were due to its suppression of NF-κB activation in macrophages, thereby inhibiting the production of proinflammatory cytokines such as TNF-α and IL-6 [59]. Furthermore, previous studies have demonstrated that specific amino acids, such as arginine and glutamine, are required for the phagocytic activity of macrophages [60, 61]. Oral administration of tryptophan has been shown to promote phagocytosis by macrophages, which might contribute to increased resistance to pathogenic infections in rats [62]. New knowledge about the role of amino acids in regulation of intestinal macrophage function is important for the development of effective strategies to prevent immunodeficient diseases.

6.3. Vitamins. Vitamin A and its derivative, retinoic acid (RA), modulate a broad spectrum of immune functions. Retinoic acid, the active metabolite of vitamin A, is produced by many subsets of intestinal antigen-presenting cells (APCs) including macrophages and dendritic cells. It has been recognized for decades that vitamin A insufficiency is related to increased susceptibility to various types of infections and impairment of both the innate and adaptive immune systems [63, 64]. Emerging evidence demonstrates that RA has an indispensable role in modulating the functions of APCs in the intestine [65, 66]. Wang et al. reported that RA suppressed IL-12 production while increasing IL-10 production in macrophages [67]. However, vitamin A deficiency was found to exacerbate inflammation in a rat model of colitis [68]. In addition, vitamin A deficiency decreased phagocytic activity and bactericidal capacity of macrophages [65]. Nevertheless, oral administration of RA can inhibit in vivo growth of Mycobacterium tuberculosis via downregulating tryptophan-aspartate-containing coat protein (TACO) gene transcription [69]. A previous study demonstrated that downregulation of TACO gene transcription can restrict entry/survival of M. tuberculosis in macrophages [70].

Vitamin D is also a strong modulator for macrophage functions. Zhang et al. found that vitamin D suppressed the production of proinflammatory cytokines in macrophages via targeting MAPK phosphatase-1 [71]. In addition, vitamin D(3)-1,25-dihydroxyvitamin D(3) directly stimulates the host defense peptide cathelicidin expression through the vitamin D receptor, which is required for the antimicrobial activity against M. tuberculosis in macrophages [72, 73]. Host
defense peptides (HDPs) constitute an important component of the innate immune system and provide immediately effective and nonspecific defenses against infections [74]. Oral supplementation of compounds that induce HDP synthesis has recently become a novel and promising strategy to prevent and control infections in both humans and animals [75, 76]. Myeloid cells, especially macrophages and neutrophils, are major sources of most HDPs. Therefore, the induction of HDPs represents another important mechanism in enhancing macrophage function by vitamin D.

7. Conclusion

Macrophages are indispensable modulators of the innate immune system because they maintain a delicate balance between immunity against pathogenic bacteria and tolerance of commensals in the intestine. Nutritional modulation of intestinal macrophages is becoming a promising approach to disease prevention and has attracted considerable attention. A better understanding of mechanisms employed by intestinal macrophages in maintaining intestinal homeostasis and the action of enteral nutrients in the regulation of intestinal macrophages will facilitate the development of nutritional strategies in gut health improvement as well as prevention and control of inflammatory bowel disorders.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This project has been supported and funded by the Natural Science Foundation of Hubei Province (2018CFB125).

References

[1] A. M. Mowat and W. W. Agace, “Regional specialization within the intestinal immune system,” Nature Reviews Immunology, vol. 14, no. 10, pp. 667–685, 2014.
[2] P. V. Chang, L. Hao, S. Offermanns, and R. Medzhitov, “The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 6, pp. 2247–2252, 2014.
[3] S. Tamoutounour, S. Henri, H. Ledourou et al., “CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis,” European Journal of Immunology, vol. 42, no. 12, pp. 3150–3166, 2012.
[4] V. Cerovic, C. C. Bain, A. M. Mowat, and S. W. F. Milling, “Intestinal macrophages and dendritic cells: what’s the difference?,” Trends in Immunology, vol. 35, no. 6, pp. 270–277, 2014.
[5] C. C. Bain, C. L. Scott, H. Uronen-Hansson et al., “Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors,” Mucosal Immunology, vol. 6, no. 3, pp. 498–510, 2013.
[6] C. C. Bain and A. M. Mowat, “The monocyte-macrophage axis in the intestine,” Cellular Immunology, vol. 291, no. 1-2, pp. 41–48, 2014.
[7] E. Mazzini, L. Massimiliano, G. Penna, and M. Rescigno, “Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1+ macrophages to CD103+ dendritic cells,” Immunity, vol. 40, no. 2, pp. 248–261, 2014.
[8] C. C. Bain, A. Bravo-Blas, C. L. Scott et al., “Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice,” Nature Immunology, vol. 15, no. 10, pp. 929–937, 2014.
[9] D. M. Mosser and J. P. Edwards, “Exploring the full spectrum of macrophage activation,” Nature Reviews Immunology, vol. 8, no. 12, pp. 958–969, 2008.
[10] N. V. Serbina and E. G. Pamer, “Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2,” Nature Immunology, vol. 7, no. 3, pp. 311–317, 2006.
[11] C. Shi and E. G. Pamer, “Monocyte recruitment during infection and inflammation,” Nature Reviews Immunology, vol. 11, no. 11, pp. 762–774, 2011.
[12] F. Geissmann, S. Jung, and D. R. Littman, “Blood monocytes consist of two principal subsets with distinct migratory properties,” Immunity, vol. 19, no. 1, pp. 71–82, 2003.
[13] J. R. Grainger, E. A. Wohlfert, I. J. Fuss et al., “Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection,” Nature Medicine, vol. 19, no. 6, pp. 713–721, 2013.
[14] N. Kamada and G. Nunez, “Regulation of the immune system by the resident intestinal bacteria,” Gastroenterology, vol. 146, no. 6, pp. 1477–1488, 2014.
[15] M. Saraiva and A. O’Garra, “The regulation of IL-10 production by immune cells,” Nature Reviews Immunology, vol. 10, no. 3, pp. 170–181, 2010.
[16] T. L. Denning, Y. C. Wang, S. R. Patel, I. R. Williams, and B. Pulendran, “Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses,” Nature Immunology, vol. 8, no. 10, pp. 1086–1094, 2007.
[17] U. Hadis, B. Wahl, O. Schulz et al., “Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria,” Immunity, vol. 34, no. 2, pp. 237–246, 2011.
[18] D. S. Shouval, A. Biswas, J. A. Goettler et al., “Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function,” Immunity, vol. 40, no. 5, pp. 706–719, 2014.
[19] B. Begue, J. Verdier, F. Rieux-Laucat et al., “Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 106, no. 8, pp. 1544–1555, 2011.
[20] E. Zigmond, B. Bernshtein, G. Friedlander et al., “Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis,” Immunity, vol. 40, no. 5, pp. 720–733, 2014.
[21] E. Zigmond, C. Varol, J. Farache et al., “Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells,” Immunity, vol. 37, no. 6, pp. 1076–1090, 2012.
[22] B. Weber, L. Saurer, M. Schenk, N. Dickgreber, and C. Mueller, “CX3CR1 defines functionally distinct intestinal mononuclear...
phagocyte subsets which maintain their respective functions during homeostatic and inflammatory conditions," *European Journal of Immunology*, vol. 41, no. 3, pp. 773–779, 2011.

[23] B. Weber, L. Saurer, and C. Mueller, "Intestinal macrophages: differentiation and involvement in intestinal immunopathologies," *Seminars in Immunopathology*, vol. 31, no. 2, pp. 171–184, 2009.

[24] J. Rugtveit, A. Bakka, and P. Brandtzæg, "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," *Clinical & Experimental Immunology*, vol. 110, no. 1, pp. 104–113, 1997.

[25] L. E. Smythies, M. Sellers, R. H. Clements et al., "Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bactericidal activity," *Journal of Clinical Investigation*, vol. 115, no. 1, pp. 66–75, 2005.

[26] M. Schenk, A. Bouchon, M. Colonna, and C. Mueller, "Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine," *The Journal of Immunology*, vol. 174, no. 1, pp. 517–524, 2005.

[27] A. Bouchon, J. Dietrich, and M. Colonna, "Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes," *The Journal of Immunology*, vol. 164, no. 10, pp. 4991–4995, 2000.

[28] J. L. Round, S. M. Lee, J. Li et al., "The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota," *Science*, vol. 332, no. 6032, pp. 974–977, 2011.

[29] L. Franchi, N. Kamada, Y. Nakamura et al., "NLRC4-driven production of IL-18 discriminates between pathogenic and commensal bacteria and promotes host intestinal defense," *Nature Immunology*, vol. 13, no. 5, pp. 449–456, 2012.

[30] K. J. Maloy and F. Powrie, "Intestinal homeostasis and its breakdown in inflammatory bowel disease," *Nature*, vol. 474, no. 7351, pp. 298–306, 2011.

[31] S. U. Seo, P. Kuffa, S. Kitamoto et al., "Intestinal macrophages arising from CCR2+ monocytes control pathogen infection by activating innate lymphoid cells," *Nature Communications*, vol. 6, no. 1, p. 8010, 2015.

[32] A. Rivollier, J. He, A. Kole, V. Valatas, and B. L. Kelsall, "Inflammation switches the differentiation program of Ly6C++ monocytes from antigen-presenting macrophages to inflammatory dendritic cells in the colon," *Journal of Experimental Medicine*, vol. 209, no. 1, pp. 139–155, 2012.

[33] I. C. Arnold, S. Mathisen, J. Schulthess, C. Danne, A. N. Hegazy, and F. Powrie, "CD11c+ monocyte/macrophages promote chronic *Helicobacter hepaticus*-induced intestinal inflammation through the production of IL-23," *Mucosal Immunology*, vol. 9, no. 2, pp. 352–363, 2016.

[34] G. Chabot-Roy, P. Willson, M. Segura, S. Lacouture, and M. Gottschalk, "Phagocytosis and killing of *Streptococcus suis* by porcine neutrophils," *Microbial Pathogenesis*, vol. 41, no. 1, pp. 21–32, 2006.

[35] M. Arib, W. Meziane, S. Habi, Y. Boulaitika, H. Marchand, and J. L. Aymeric, "Macrophage bactericidal activities against *Staphylococcus aureus* are enhanced in vivo by selenium supplementation in a dose-dependent manner," *PLoS One*, vol. 10, no. 9, article e0135515, 2015.

[36] G. Marelli, M. Erreni, A. Ansello et al., "Heme-oxygenase-1 production by intestinal CX3CR1+ macrophages helps to resolve inflammation and prevents carcinogenesis," *Cancer Research*, vol. 77, no. 16, pp. 4472–4485, 2017.

[37] Y. Zheng, P. A. Valdez, D. M. Danilenko et al., "Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens," *Nature Medicine*, vol. 14, no. 3, pp. 282–289, 2008.

[38] D. Bauché, B. Joyce-Shaikh, R. Jain et al., "LAG3 regulatory T cells restrain interleukin-23-producing CX3CR1+ gut-resident macrophages during group 3 innate lymphoid cell-driven colitis," *Immunity*, vol. 49, no. 2, pp. 342–352.e5, 2018.

[39] W. Ouyang, J. K. Kolls, and Y. Zheng, "The biological functions of Thelper 17 cell effector cytokines in inflammation," *Immunity*, vol. 28, no. 4, pp. 454–467, 2008.

[40] S. J. Rhee, W. A. Walker, and B. J. Cheryali, "Developmentally regulated intestinal expression of IFN-γ and its target genes and the age-specific response to enteric *Salmonella* infection," *The Journal of Immunology*, vol. 175, no. 2, pp. 1127–1136, 2005.

[41] S. Z. Sheikh and S. E. Plevy, "The role of the macrophage in sentinel responses in intestinal immunity," *Current Opinion in Gastroenterology*, vol. 26, no. 6, pp. 578–582, 2010.

[42] E. Zigmond and S. Jung, "Intestinal macrophages: well educated exceptions from the rule," *Trends in Immunology*, vol. 34, no. 4, pp. 162–168, 2013.

[43] S. Z. Josefowicz, R. E. Nicc, H. Y. Kim et al., "Extra-thymically generated regulatory T cells control mucosal T_{H}2 inflammation," *Nature*, vol. 482, no. 7385, pp. 395–399, 2012.

[44] T. L. Denning, B. A. Norris, O. Medina-Contreras et al., "Functional specialization of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization," *The Journal of Immunology*, vol. 187, no. 2, pp. 733–747, 2011.

[45] R. J. Xavier and D. K. Podolsky, "Unravelling the pathogenesis of inflammatory bowel disease," *Nature*, vol. 448, no. 7152, pp. 427–434, 2007.

[46] M. Quiros, H. Nishio, P. A. Neumann et al., "Macrophage-derived IL-10 mediates mucosal repair by epithelial WISP-1 signaling," *Journal of Clinical Investigation*, vol. 127, no. 9, pp. 3510–3520, 2017.

[47] J. Cosín-Roger, D. Ortíz-Masiá, S. Calatayud, C. Hernández, J. V. Esplugues, and M. D. Barrachina, "The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD," *Mucosal Immunology*, vol. 9, no. 4, pp. 986–998, 2016.

[48] F. D’Angelo, E. Bernasconi, M. Schäfer et al., "Macrophages promote epithelial repair through hepatocyte growth factor secretion," *Clinical & Experimental Immunology*, vol. 174, no. 1, pp. 60–72, 2013.

[49] S. H. Chang, P. Kundu, C. Dominguez-Brauer et al., "Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity," *Scientific Reports*, vol. 6, no. 1, article 23820, 2016.

[50] G. Marelli, P. Allavena, and M. Erreni, "Tumor-associated macrophages, multi-tasking cells in the cancer landscape," *Cancer Research Frontiers*, vol. 1, no. 2, pp. 149–161, 2015.

[51] M. Kinoshita, H. Kayama, T. Kusu et al., "Tissue-specific exceptions from the rule," *The Journal of Immunology*, vol. 184, no. 3, pp. 2869–2878, 2012.

[52] T. Ochi, Y. Feng, S. Kitamoto et al., "Diet-dependent, microbiota-independent regulation of IL-10-producing lamina
propria macrophages in the small intestine," *Scientific Reports*, vol. 6, no. 1, article 27634, 2016.

[53] W. R. Russell, L. Hoyles, H. J. Flint, and M. E. Dumas, "Colonial bacterial metabolites and human health," *Current Opinion in Microbiology*, vol. 16, no. 3, pp. 246–254, 2013.

[54] W. Scheppech and German-Austrian ScaF Study Group, "Treatment of distal ulcerative colitis with short-chain fatty acid enemas a placebo-controlled trial," *Digestive Diseases and Sciences*, vol. 41, no. 11, pp. 2254–2259, 1996.

[55] E. L. M. Vieira, A. J. Leonel, A. P. Sad et al., "Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis," *The Journal of Nutritional Biochemistry*, vol. 23, no. 5, pp. 430–436, 2012.

[56] S. Tedelind, F. Westberg, M. Kjerrulf, and A. Vidal, "Vitamin and propionate: a study with relevance to inflammatory bowel disease," *World Journal of Gastroenterology*, vol. 13, no. 20, pp. 2826–2832, 2007.

[57] C. Iraporda, A. Errea, D. E. Romanin et al., "Lactate and short chain fatty acids produced by microbial fermentation down-regulate proinflammatory responses in intestinal epithelial cells and myeloid cells," *Immunobiology*, vol. 220, no. 10, pp. 1161–1169, 2015.

[58] H. Liu, J. Wang, T. He et al., "Butyrate: a double-edged sword for health?", *Advances in Nutrition*, vol. 9, no. 1, pp. 21–29, 2018.

[59] A. Andou, T. Hisamatsu, S. Okamoto et al., "Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokines production from macrophages," *Gastroenterology*, vol. 136, no. 2, pp. 564–574.e2, 2009.

[60] P. Newsholme, J. Procopio, M. M. R. Lima, T. C. Pithon-Curi, and R. Curi, "Glutamine and glutamate—their central role in cell metabolism and function," *Cell Biochemistry and Function*, vol. 21, no. 1, pp. 1–9, 2003.

[61] P. Li, Y. L. Yin, D. Li, S. W. Kim, and G. Wu, "Amino acids and immune function," *British Journal of Nutrition*, vol. 98, no. 2, pp. 237–252, 2007.

[62] S. Esteban, C. Nicolaus, A. Garmundi et al., "Effect of orally administered L-tryptophan on serotonin, melatonin, and the innate immune response in the rat," *Molecular and Cellular Biochemistry*, vol. 267, no. 1/2, pp. 39–46, 2004.

[63] M. Iwata, A. Hirakiyama, Y. Eshima, H. Kagechika, C. Kato, and S. Y. Song, "Retinoic acid imprints gut-homing specificity on T cells," *Immunity*, vol. 21, no. 4, pp. 527–538, 2004.

[64] J. R. Mora, M. Iwata, B. Eksteen et al., "Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells," *Science*, vol. 314, no. 5802, pp. 1157–1160, 2006.

[65] S. Manicassamy and B. Pulendran, "Retinoic acid-dependent regulation of immune responses by dendritic cells and macrophages," *Seminars in Immunopathology*, vol. 21, no. 1, pp. 22–27, 2009.

[66] J. A. Hall, J. R. Grainger, S. P. Spencer, and Y. Bellkaid, "The role of retinoic acid in tolerance and immunity," *Immunity*, vol. 35, no. 1, pp. 13–22, 2011.

[67] X. Wang, C. Allen, and M. Ballow, "Retinoic acid enhances the production of IL-10 while reducing the synthesis of IL-12 and TNF-α from LPS-stimulated monocytes/macrophages," *Journal of Clinical Immunology*, vol. 27, no. 2, pp. 193–200, 2007.

[68] R. Reifen, T. Nur, K. Ghebermeskel, G. Zaiger, R. Urizky, and M. Pines, "Vitamin A deficiency exacerbates inflammation in a rat model of colitis through activation of nuclear factor-κB and collagen formation," *The Journal of Nutrition*, vol. 132, no. 9, pp. 2743–2747, 2002.

[69] H. Yamada, S. Mizuno, A. C. Ross, and I. Sugawara, "Retinoic acid therapy attenuates the severity of tuberculosis while altering lymphocyte and macrophage numbers and cytokine expression in rats infected with *Mycobacterium tuberculosis*," *The Journal of Nutrition*, vol. 137, no. 12, pp. 2696–2700, 2007.

[70] P. K. Anand and D. Kaul, "Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages," *FEMS Microbiology Letters*, vol. 250, no. 1, pp. 137–144, 2005.

[71] Y. Zhang, D. Y. M. Leung, B. N. Richers et al., "Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1," *The Journal of Immunology*, vol. 188, no. 5, pp. 2127–2135, 2012.

[72] T. T. Wang, F. P. Nestel, V. Bourdeau et al., "Cutting edge: 1,25-dihydroxyvitamin D₃ is a direct inducer of antimicrobial peptide gene expression," *The Journal of Immunology*, vol. 173, no. 5, pp. 2909–2912, 2004.

[73] M. Fabri, S. Stenger, D. M. Shin et al., "Vitamin D is required for IFN-γ-mediated antimicrobial activity of human macrophages," *Science Translational Medicine*, vol. 3, no. 104, article 104ra102, 2011.

[74] S. Wang, X. Zeng, Q. Yang, and S. Qiao, "Antimicrobial peptides as potential alternatives to antibiotics in food animal industry," *International Journal of Molecular Sciences*, vol. 17, no. 5, 2016.

[75] W. Lyu, A. Curtis, L. Sunkara, and G. Zhang, "Transcriptional regulation of antimicrobial host defense peptides," *Current Protein and Peptide Science*, vol. 16, no. 7, pp. 672–679, 2015.

[76] K. Robinson, X. Ma, Y. Liu, S. Qiao, Y. Hou, and G. Zhang, "Dietary modulation of endogenous host defense peptide synthesis as an alternative approach to in-feed antibiotics," *Animal Nutrition*, vol. 4, no. 2, pp. 160–169, 2018.